RxDoctor Payments DataLook up a doctor →

Scott Macdiarmid, MD

Urology · Greensboro, NCNPI 1346222775

Payments from drug & device makers

$881,990in general payments, 2019–2025

Across 817 payments — averaging $1079.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Valencia Technologies Corporation$284K
  • Laborie Medical Technologies Corp.$144K
  • Sumitomo Pharma America, Inc.$99K
  • Medtronic$92K
  • Urovant Sciences Inc$87K
  • Ferring Pharmaceuticals Inc.$63K
  • plus $112K from 32 others
$4,032in research payments, 2019–2025

Across 4 payments — averaging $1007.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$4K

What the payments were for

  • Consulting fees$464,35260%
  • Speaking & faculty fees$219,38228%
  • Travel & lodging$72,6249%
  • Food & beverage$16,1202%
  • Education$1,1930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$881,990 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$167,447
Medicare patients
395
Services billed
5,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron750$518,486
GemtesaVibegron579$465,847
ElmironPentosan Polysulfate Sodium48$48,879
Trimethoprim750$35,527
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst433$17,383
NitrofurantoinNitrofurantoin Macrocrystal441$13,404
Oxybutynin Chloride ErOxybutynin Chloride562$10,571
Solifenacin Succinate328$9,245
Cephalexin367$7,969
Tolterodine Tartrate ErTolterodine Tartrate86$7,444
Fesoterodine Fumarate ErFesoterodine Fumarate55$6,639
PremarinEstrogens, Conjugated11$4,846
Tamsulosin Hcl339$4,699
Estradiol49$3,227
ToviazFesoterodine Fumarate12$2,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$54,966$518,486750 claims
Sumitomo Pharma America, Inc.Gemtesa$99,252$465,847579 claims
PfizerPremarin, Toviaz$274$6,94723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 urology providers in North Carolina.

Other urology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →